INVENTIVA (EPA:IVA) | WebDisclosure

Basculer en Français

10940	Companies
239029	Keywords
167904	Articles
128527	Press releases

Home
Companies
INVENTIVA

BRIEF

published on 09/02/2026 at 22:10, 5 days 4 hours ago

Inventiva franchit une étape clé dans son essai clinique MASH

Biopharmaceutique Inventive Lanifibranor Traitement MASH Essai NATiV3
BRIEF

published on 09/02/2026 at 22:10, 5 days 4 hours ago

Inventiva Completes Final Visit of the NATiV3 Lanifibranor Study

Clinical Study Phase 3 Inventiva MASH Lanifibranor
BRIEF

published on 09/02/2026 at 22:10, 5 days 4 hours ago

Inventiva Completes Key Milestone in MASH Clinical Trial

Biopharmaceutical Inventiva Lanifibranor MASH Treatment NATiV3 Trial
BRIEF

published on 09/02/2026 at 22:10, 5 days 4 hours ago

Inventiva Achève la Visite Finale de l'Étude NATiV3 sur le Lanifibranor

Étude Clinique Phase 3 Inventiva MASH Lanifibranor
PRESS RELEASE

published on 09/02/2026 at 22:05, 5 days 4 hours ago

Inventiva annonce la dernière visite du dernier patient de l’étude clinique de Phase 3 NATiV3 évaluant le lanifibranor dans la MASH
Inventiva annonce la fin de l'étude clinique de Phase 3 NATiV3 évaluant le lanifibranor dans la MASH, avec les résultats attendus au quatrième trimestre 2026

Étude Clinique Phase 3 Inventiva MASH Lanifibranor
PRESS RELEASE

published on 09/02/2026 at 22:05, 5 days 4 hours ago

Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
Inventiva completes last patient visit in Phase 3 trial for lanifibranor in MASH treatment, with topline results expected in Q4 2026. Financial results update scheduled for H1 2026

Phase 3 Trial Inventiva Lanifibranor MASH Treatment Financial Results Update
BRIEF

published on 08/31/2026 at 22:10, 7 days 4 hours ago

Chris Benecchi nommé COO par Inventiva

Biopharmaceutique Inventiva MASH Lanifibranor Chris Benecchi
BRIEF

published on 08/31/2026 at 22:10, 7 days 4 hours ago

Chris Benecchi appointed COO by Inventiva

Biopharmaceutical Inventiva MASH Lanifibranor Chris Benecchi
BRIEF

published on 08/31/2026 at 22:10, 7 days 4 hours ago

Inventiva Appoints Chris Benecchi as Chief Operating Officer

Biopharmaceutical Phase 3 Study Inventiva Lanifibranor Chris Benecchi
BRIEF

published on 08/31/2026 at 22:10, 7 days 4 hours ago

Inventiva nomme Chris Benecchi au poste de directeur de l'exploitation

Biopharmaceutique Étude De Phase 3 Inventive Lanifibranor Chris Benecchi

Accesswire

Published on 09/08/2026 at 01:45, 1 hour 14 minutes ago

Tunkillia Environmental Scoping Report Approved
Published on 09/05/2026 at 04:05, 2 days 22 hours ago

Pelican AI Corp. Announces Proposed Share Issuances and Litigation Update
Published on 09/04/2026 at 23:30, 3 days 3 hours ago

FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 3 days 3 hours ago

Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 3 days 4 hours ago

Panther Minerals Closes Brokered Private Placement of $3,000,000

View all ACCESSWIRE

EQS Group

Published on 09/07/2026 at 19:19, 7 hours 40 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Sales and Adjusted EBIT in Q2 2026/27 above prior-year level – FY outlook maintained
Published on 09/07/2026 at 19:00, 7 hours 59 minutes ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 31 août 2026 au 4 septembre 2026
Published on 09/07/2026 at 18:42, 8 hours 17 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/07/2026 at 18:00, 8 hours 59 minutes ago

E-PANGO: e-Pango organise un webinaire avec ses actionnaires
Published on 09/07/2026 at 17:45, 9 hours 14 minutes ago

VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social

Les Echos

Published on 09/07/2026 at 19:55, 7 hours 4 minutes ago

TFF GROUP CREE TFF UPCYCLING
Published on 09/07/2026 at 19:00, 7 hours 59 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 4 septembre 2026
Published on 09/07/2026 at 19:00, 7 hours 59 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of September 4, 2026
Published on 09/07/2026 at 18:05, 8 hours 54 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/08/2026
Published on 09/07/2026 at 18:05, 8 hours 54 minutes ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/08/2026

View all LES ECHOS COMFI WIRE